Invasive versus medically managed acute coronary syndromes with prior bypass (CABG-ACS): insights into the registry versus randomised trial populations


ABSTRACT

Background Coronary artery bypass graft (CABG) patients are under-represented in acute coronary syndrome (ACS) trials. We compared characteristics and outcomes for patients who did and did not participate in a randomised trial of invasive versus non-invasive management (CABG-ACS).

Methods ACS patients with prior CABG in four hospitals were randomised to invasive or non-invasive management. Non-randomised patients entered a registry. Primary efficacy (composite of all-cause mortality, rehospitalisation for refractory ischaemia/angina, myocardial infarction (MI), heart failure) and safety outcomes (composite of bleeding, stroke, procedure-related MI, worsening renal function) were independently adjudicated.

Results Of 217 patients screened, 84 (39%) screenfailed, of whom 24 (29%) did not consent and 60 (71%) were ineligible. Of 133 (61%) eligible, 60 (mean±SD age, 71±9 years, 72% male) entered the trial and 73 (age, 72±10 years, 72% male) entered a registry (preferences: physician (79%), patient (38%), both (21%)). Compared with trial participants, registry patients had more valve disease, lower haemoglobin, worse New York Heart Association class and higher frailty. At baseline, invasive management was performed in 52% and 49% trial and registry patients, respectively, of whom 32% and 36% had percutaneous coronary intervention at baseline, respectively (p=0.800). After 2 years follow-up (694 (median, IQR 558–841) days), primary efficacy (43% trial vs 49% registry (HR 1.14, 95% CI 0.69 to 1.89)) and safety outcomes (28% trial vs 22% registry (HR 0.74, 95% CI 0.37 to 1.46)) were similar. EuroQol was lower in registry patients at 1 year.

Conclusions Compared with trial participants, registry participants had excess morbidity, but longer-term outcomes were similar.

Trial registration number NCT01895751.

INTRODUCTION

Coronary artery bypass graft (CABG) surgery is standard of care for patients with obstructive coronary artery disease. However, occlusive disease of saphenous vein grafts is common within 10 years of surgery, meaning patients with prior CABG have a progressive longer-term risk of recurrent ischaemia, including angina and myocardial infarction (MI), heart failure (HF) and death. Given the large number of CABG recipients living globally, and their health complexities, including increasing age and multimorbidity, this represents an increasing healthcare challenge globally.

Key questions

What is already known about this subject?

▸ Pivotal clinical trials of invasive management versus non-invasive medical management in acute coronary syndromes (ACS) excluded patients with prior CABG.

What does this study add?

▸ The CABG-ACS trial and registry provides novel, contemporary insights into an understudied subgroup of ACS patients with a substantial health burden.

How might this impact on clinical practice?

▸ The CABG-ACS pilot trial and registry fills in an evidence gap on the natural history and optimal treatment strategy for this comparatively large subgroup of patients. Furthermore, the CABG-ACS trial and registry may be helpful in the design of clinical trials in this patient group.
not least because of rehospitalisation due to recurrent ischaemia. Chest pain is the most common reason for hospital admission in the UK and about 1 in 10–15 patients admitted to hospital with an acute non-ST segment elevation acute coronary syndrome (NSTE-ACS) have a prior CABG. Pivotal clinical trials comparing routine invasive management vs conservative non-invasive management in unstable coronary syndromes excluded patients with prior CABG (online supplemental table 1). Current guidelines recommend a routine early invasive strategy in higher risk NSTE-ACS patients. However, invasive management is performed less often in NSTE-ACS patients with prior CABG, probably because the risk:benefit balance is considered to be less favourable in these patients compared with those without prior CABG. Furthermore, when invasive management is performed, percutaneous coronary intervention (PCI) is less likely in prior CABG patients, implying a lower likelihood of benefit with a routine invasive strategy. Real-world evidence implies clinical practice departs from the results of systematic reviews and guidelines, indicating physician and patient preferences for treatment options may be relevant. Overall, evidence is lacking to inform the validity of current guideline recommendations in NSTE-ACS patients with prior CABG. This important subgroup of ACS patients remains comparatively understudied. Enrolment into randomised trials can be challenging, particularly when the intervention disrupts standard care. Enrolment of elderly patients may be challenging, sometimes leading to premature trial discontinuation.

We hypothesised that the clinical characteristics, treatment and health outcomes would differ between participants enrolled in a randomised controlled trial of routine invasive versus routine non-invasive management in NSTE-ACS patients with prior CABG, and participants enrolled in the registry due to physician and/or patient preference. We aimed to prospectively gather information on the trial and registry participants in order to gain contemporary information on the natural history and reasons for trial participation or not.

METHODS

We undertook a randomised controlled trial of routine invasive management vs routine conservative management in NSTE-ACS patients with prior CABG. Currently, patients who were ineligible for randomisation and who gave informed consent were entered into an observational registry. The study design, and results of the main trial have been published.

Study population

Inclusion criteria were: (1) unstable angina or non-ST segment elevation MI; (2) stabilised symptoms without recurrent chest pain or intravenous therapy for 12 hours and (3) prior CABG. Exclusion criteria were: (1) refractory ischaemia (ie, recurrent angina with minimal exertion or at rest (ie, Canadian Cardiovascular Society (CCS) class III or IV) not controlled by medical therapy); (2) cardiogenic shock; (3) lack of informed consent and (4) unsuitable for invasive management.

Randomisation

Patients fulfilling inclusion criteria without any exclusion criteria who consented to participate in the randomised trial were enrolled (figure 1). Randomisation was performed by the Trials Unit interactive voice recognition system to one of two groups: initial medical management or initial invasive management (online supplemental methods).

Registry

Information was prospectively recorded in a registry for acute NSTE-ACS and prior CABG patients who were not randomised but consented to participate in the registry. Reasons for non-participation in the randomised trial were prospectively recorded: exclusion criteria present, unsuitability for either invasive or non-invasive management, physician preference, patient preference or a combination of these factors. Baseline and follow-up clinical information were obtained similarly to the trial patients.
## Table 1  Baseline clinical characteristics of the trial and registry participants

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Statistic</th>
<th>All N=133</th>
<th>Trial N=60</th>
<th>Registry N=73</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td>Mean±SD</td>
<td>71±10</td>
<td>71±9</td>
<td>72±10</td>
<td>0.46</td>
</tr>
<tr>
<td>Female sex</td>
<td>N (%)</td>
<td>37 (28)</td>
<td>17 (28)</td>
<td>20 (27)</td>
<td>1.00</td>
</tr>
<tr>
<td>Obese (body mass index &gt;30 kg/m²)</td>
<td>N (%)</td>
<td>37 (28)</td>
<td>22 (37)</td>
<td>15 (21)</td>
<td>0.05</td>
</tr>
<tr>
<td><strong>Presentation type</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-ST segment elevation MI</td>
<td>N (%)</td>
<td>90 (68)</td>
<td>41 (68)</td>
<td>49 (67)</td>
<td>1.00</td>
</tr>
<tr>
<td>Unstable angina</td>
<td>N (%)</td>
<td>43 (32)</td>
<td>19 (32)</td>
<td>24 (33)</td>
<td>1.00</td>
</tr>
<tr>
<td><strong>Medical history</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus†</td>
<td>N (%)</td>
<td>50 (38)</td>
<td>21 (35)</td>
<td>29 (40)</td>
<td>0.60</td>
</tr>
<tr>
<td>Previous MI</td>
<td>N (%)</td>
<td>91 (68)</td>
<td>41 (68)</td>
<td>50 (68)</td>
<td>1.00</td>
</tr>
<tr>
<td>Cardiac arrhythmia</td>
<td>N (%)</td>
<td>47 (36)</td>
<td>19 (32)</td>
<td>28 (39)</td>
<td>0.37</td>
</tr>
<tr>
<td>Treated hypertension</td>
<td>N (%)</td>
<td>88 (66)</td>
<td>42 (70)</td>
<td>46 (63)</td>
<td>0.46</td>
</tr>
<tr>
<td>Renal impairment</td>
<td>N (%)</td>
<td>38 (29)</td>
<td>13 (22)</td>
<td>25 (34)</td>
<td>0.13</td>
</tr>
<tr>
<td>Peripheral vascular disease</td>
<td>N (%)</td>
<td>32 (24)</td>
<td>16 (27)</td>
<td>16 (22)</td>
<td>0.55</td>
</tr>
<tr>
<td>Congestive HF</td>
<td>N (%)</td>
<td>30 (23)</td>
<td>13 (22)</td>
<td>17 (23)</td>
<td>0.84</td>
</tr>
<tr>
<td>Anaemia</td>
<td>N (%)</td>
<td>44 (33)</td>
<td>14 (23)</td>
<td>30 (41)</td>
<td>0.04</td>
</tr>
<tr>
<td>Valve disease</td>
<td>N (%)</td>
<td>20 (15)</td>
<td>5 (8)</td>
<td>15 (21)</td>
<td>0.05</td>
</tr>
<tr>
<td>Pacemaker</td>
<td>N (%)</td>
<td>43 (32)</td>
<td>12 (20)</td>
<td>31 (42)</td>
<td>0.01</td>
</tr>
<tr>
<td><strong>History of smoking</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>N (%)</td>
<td>27 (20)</td>
<td>12 (20)</td>
<td>15 (21)</td>
<td>0.35</td>
</tr>
<tr>
<td>Former (&gt;3 months)</td>
<td>N (%)</td>
<td>80 (60)</td>
<td>33 (55)</td>
<td>47 (64)</td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>N (%)</td>
<td>26 (20)</td>
<td>15 (25)</td>
<td>11 (15)</td>
<td></td>
</tr>
<tr>
<td>Serum creatinine, μmol/L</td>
<td>Median (IQR)</td>
<td>86 (71–114)</td>
<td>84 (68–101)</td>
<td>89 (73–131)</td>
<td>0.11</td>
</tr>
<tr>
<td>Haemoglobin, g/L</td>
<td>Mean±SD</td>
<td>131±18</td>
<td>135±16</td>
<td>127±18</td>
<td>0.01</td>
</tr>
<tr>
<td>Charlson Comorbidity Index</td>
<td>Median (IQR)</td>
<td>5 (3–7)</td>
<td>4 (3–6)</td>
<td>5 (3–7)</td>
<td>0.28</td>
</tr>
<tr>
<td>Health-related quality of life, EuroQol 5 Dimensions 5 Levels score</td>
<td>Median (IQR)</td>
<td>0.674 (0.447–0.866)</td>
<td>0.748 (0.514–0.899)</td>
<td>0.658 (0.437–0.817)</td>
<td>0.11</td>
</tr>
<tr>
<td><strong>ECG abnormalities at initial presentation</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ST-segment depression</td>
<td>N (%)</td>
<td>67 (50)</td>
<td>28 (47)</td>
<td>39 (53)</td>
<td>0.49</td>
</tr>
<tr>
<td>ST-segment elevation</td>
<td>N (%)</td>
<td>27 (20)</td>
<td>11 (18)</td>
<td>16 (22)</td>
<td>0.67</td>
</tr>
<tr>
<td>T-wave inversion</td>
<td>N (%)</td>
<td>89 (67)</td>
<td>38 (63)</td>
<td>51 (70)</td>
<td>0.46</td>
</tr>
<tr>
<td>Q-waves</td>
<td>N (%)</td>
<td>42 (32)</td>
<td>15 (25)</td>
<td>27 (37)</td>
<td>0.19</td>
</tr>
<tr>
<td>Left bundle branch block</td>
<td>N (%)</td>
<td>11 (8)</td>
<td>5 (8)</td>
<td>6 (8)</td>
<td>1.00</td>
</tr>
<tr>
<td>AF or flutter</td>
<td>N (%)</td>
<td>23 (17)</td>
<td>9 (15)</td>
<td>14 (19)</td>
<td>0.65</td>
</tr>
<tr>
<td>New ischaemic ECG changes‡</td>
<td>N (%)</td>
<td>66 (50)</td>
<td>30 (50)</td>
<td>36 (50)</td>
<td>1.00</td>
</tr>
<tr>
<td><strong>Canadian Cardiovascular Society angina class</strong>§</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>N (%)</td>
<td>4 (3)</td>
<td>2 (3)</td>
<td>2 (3)</td>
<td>0.83</td>
</tr>
<tr>
<td>2</td>
<td>N (%)</td>
<td>11 (8)</td>
<td>6 (10)</td>
<td>5 (7)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>N (%)</td>
<td>26 (20)</td>
<td>10 (17)</td>
<td>16 (22)</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>N (%)</td>
<td>90 (69)</td>
<td>41 (69)</td>
<td>49 (68)</td>
<td></td>
</tr>
</tbody>
</table>

New York Heart Association functional class

Continued
Follow-Up

Follow-up (via telephone contact, clinic visits, letter) with completion of quality of life assessments (EuroQol Visual Analogue Scale (EQ-VAS) and EuroQol 5 Dimensions 5 Levels (EQ-5D-5L)) was maintained 6 monthly until ≥18 months follow-up was reached for the final recruited patient (online supplemental methods).

Clinical event committee

An independent clinical event committee reviewed the primary efficacy and safety endpoints (online supplemental methods).

Table 1

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Statistic</th>
<th>All N=133</th>
<th>Trial N=60</th>
<th>Registry N=73</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>N (%)</td>
<td>47 (35)</td>
<td>30 (50)</td>
<td>17 (23)</td>
<td>0.01</td>
</tr>
<tr>
<td>II</td>
<td>N (%)</td>
<td>47 (35)</td>
<td>18 (30)</td>
<td>29 (40)</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>N (%)</td>
<td>28 (21)</td>
<td>8 (13)</td>
<td>20 (27)</td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>N (%)</td>
<td>11 (8)</td>
<td>4 (7)</td>
<td>7 (10)</td>
<td></td>
</tr>
</tbody>
</table>

Coronary artery bypass grafts

| Left internal mammary artery | N (%)         | 109 (82) | 50 (83) | 59 (81) | 0.82 |
| No/unknown                  | N (%)         | 24 (18)  | 10 (17) | 14 (19) |       |

Saphenous vein graft

| 0                           | N (%)         | 10 (8)   | 3 (5)   | 7 (10)  | 0.74 |
| 1                           | N (%)         | 37 (29)  | 17 (29) | 20 (29) |       |
| 2                           | N (%)         | 54 (43)  | 25 (43) | 29 (43) |       |
| ≥3                          | N (%)         | 25 (20)  | 13 (22) | 12 (18) |       |

Frailty index

| Fit or well (1,2,3) | N (%)         | 60 (45)  | 35 (58) | 25 (34) | 0.03 |
| Vulnerable (4) or mildly frail (5) | N (%)         | 42 (32)  | 14 (23) | 28 (38) |       |
| Moderately frail (6) | N (%)         | 29 (22)  | 10 (17) | 19 (26) |       |
| Severely frail (7)   | N (%)         | 2 (2)    | 1 (2)   | 1 (1)   |       |

Medication prior to hospital admission

| Aspirin                | N (%)         | 113 (85) | 52 (87) | 61 (84) | 0.81 |
| Statin                 | N (%)         | 113 (85) | 55 (92) | 58 (79) | 0.06 |
| Beta-blocker           | N (%)         | 94 (71)  | 42 (70) | 52 (71) | 1.00 |
| Calcium channel blocker| N (%)         | 133 (100)| 60 (100)| 73 (100)| 1.00 |
| Isosorbide mononitrate | N (%)         | 50 (38)  | 20 (33) | 30 (41) | 0.38 |
| Nicorandil             | N (%)         | 47 (35)  | 22 (37) | 25 (34) | 0.86 |
| ACE inhibitor          | N (%)         | 101 (76) | 50 (83) | 51 (70) | 0.10 |
| Insulin                | N (%)         | 20 (15)  | 10 (17) | 10 (14) | 0.64 |
| Oral antidiabetic therapy | N (%)         | 28 (21)  | 10 (17) | 18 (25) | 0.29 |
| Antidepressant therapy | N (%)         | 24 (18)  | 13 (22) | 11 (15) | 0.37 |
| Diuretic               | N (%)         | 52 (39)  | 18 (30) | 34 (47) | 0.07 |

Note that where there are missing values, the percentages are calculated out of the number of patients with data. Cardiac arrhythmia (2 missing from registry). New ischaemic ECG changes (1 missing from registry). Canadian Cardiovascular Society angina class (1 missing from trial, 1 missing from registry). Saphenous vein graft (2 missing from trial, 5 missing from registry). Mean ± SD or median (IQR) for normal and non-normally distributed data, respectively.

* During the index hospitalisation, all patients in the randomised trial group had a type 1 MI, while seven patients in the registry group did not have a type 1 MI but had a type 2 MI (2 AF, 1 AF+HF, 1 severe aortic stenosis+HF, 1 anaemia, 1 AF+acute kidney injury, 1 HF+respiratory tract infection).
† Diabetes mellitus was defined as a history of diet-controlled or treated diabetes.
‡ Any previous episode with new ischaemic ECG changes.
§ The highest Canadian Cardiovascular Society value of any previous episode for each patient.
ACE, Angiotensin-converting enzyme; AF, atrial fibrillation; HF, heart failure; MI, myocardial infarction.
Outcomes

Primary outcome
Defined as postrandomisation rate of major adverse events (coprimary composite outcome), including one composite outcome for efficacy and one composite outcome for safety.

Primary efficacy outcome
Defined as bleeding (Bleeding Academic Research Consortium (BARC) types 2–4), stroke, procedure-related MI (type 4a, universal definition), worsening renal function or haemodialysis during the index hospitalisation.

Secondary outcomes
1. Quality of life.
2. CCS angina class.
3. Hospitalisation for refractory ischaemia and/or angina.
4. Repeat invasive management during follow-up.
5. Freedom from coronary and/or bypass graft intervention.

Definitions of adverse events
Refractory ischaemia, death, procedure-related MI, stroke, major bleeding and worsening renal function are defined in online supplemental methods.

Table 2 Reasons for changing medical therapy during the index hospitalisation

<table>
<thead>
<tr>
<th>Reason</th>
<th>All N=133 (%)</th>
<th>Trial N=60 (%)</th>
<th>Registry N=73 (%)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recurrent angina</td>
<td>47 (35)</td>
<td>13 (22)</td>
<td>34 (47)</td>
<td>0.003</td>
</tr>
<tr>
<td>Standard optimisation of secondary prevention therapy</td>
<td>103 (77)</td>
<td>54 (90)</td>
<td>49 (67)</td>
<td>0.002</td>
</tr>
<tr>
<td>Intolerance of therapy without adverse reaction</td>
<td>8 (6)</td>
<td>2 (3)</td>
<td>6 (8)</td>
<td>0.293</td>
</tr>
<tr>
<td>Adverse drug reaction</td>
<td>10 (8)</td>
<td>2 (3)</td>
<td>8 (11)</td>
<td>0.113</td>
</tr>
<tr>
<td>Other</td>
<td>7 (5)</td>
<td>3 (5)</td>
<td>4 (5)</td>
<td>1.000</td>
</tr>
</tbody>
</table>

RESULTS

Two hundred and seventeen patients with prior CABG and an unplanned hospitalisation for a suspected NSTE-ACS were screened (figure 1).

Eighty-four (39%) participants were identified during screening but were deemed ineligible for progressing into the trial or registry, of whom 24 (29%) did not consent and 60 (71%) consented but were ineligible (21 reason): 42 (70%) not confirmed NSTE-ACS, 39 (65%) not stabilised symptoms, 4 (7%) no prior CABG, 5 (8%) refractory ischaemia, 3 (5%) unable to provide informed consent and 22 (37%) unsuitable for invasive management.

Of 133 (61%) eligible patients who consented to either the trial or registry, 60 patients (mean±SD age, 71±9 years, 43 (72%) male) were randomised and 73 (mean±SD age, 72±10 years, 53 (73%) male) entered the registry. The decision for entering the registry included physician preference (58 (79%)), patient preference (28 (38%)) or both (15 (21%)).

Baseline characteristics
The characteristics of the trial and registry participants are described (table 1). Compared with trial participants, registry patients were twice as likely to have valve disease (31 (42%) vs 12 (20%); p=0.01), a lower haemoglobin (mean±SD 127±18 vs 135±16 g/L; p=0.01), worse New York Heart Association class (37% vs 20% in class III or IV; p=0.01) and higher frailty index (27% vs 18% moderately or severely frail and 38% vs 23% mildly frail; p=0.03). Fifty (83%) trial and 59 (81%) registry patients participants had a previous left internal mammary artery graft (p=0.82). Baseline EQ-5D, EQ-5D-5L and medications were similar.

In-hospital clinical course and invasive management
More than twice as many patients in the registry versus the trial had a medication change for recurrent angina. Approximately three-quarters of registry patients had medication changes for standard optimisation of secondary prevention therapy compared with trial patients (table 2).

At baseline, invasive management (coronary angiography±PCI) was undertaken in 31 (52%) and 36 (49%) patients in the trial and registry groups, respectively, increasing during follow-up to 46 (77%) and 40 (55%), respectively (table 3). Of those who had invasive management at baseline and follow-up, PCI was performed in 10 (22%) and 13 (33%) of trial and registry patients at baseline, increasing to 21 (46%) and 18 (45%) patients during follow-up, respectively (table 3). For baseline procedures, the British Cardiovascular Intervention Society-1 Jeopardy Score was similar between trial (4±4) and registry (5±3; p=0.19) patients (table 3). At baseline and follow-up, compared with trial patients, registry patients had more urgent inpatient invasive procedures (39 (75%) vs 27 (47%)) and fewer outpatient invasive procedures (13 (25%) vs 30 (53%); p=0.004) (table 3). The culprit lesion was uncertain in 27 (47%) and 21 (40%) of procedures in the trial and registry groups, respectively (table 3).
Adoption of adjunctive techniques, for example, rotational atherectomy was low (table 3).

Health outcomes
During a median of 694 (IQR 558–841) days follow-up, the primary efficacy outcome occurred in 26 (43%) and 36 (49%) trial and registry participants, respectively (HR 1.14, 95% CI 0.69 to 1.89) (table 4). The primary safety outcome occurred in 17 (28%) and 16 (22%) trial and registry participants, respectively (HR 0.74, 95% CI 0.37 to 1.46). The observed proportion of registry patients experiencing the efficacy outcome was slightly higher than in the trial group, whereas the opposite occurred for the safety outcome

### Table 3

<table>
<thead>
<tr>
<th>Patients with procedures at baseline and follow-up</th>
<th>Trial N=46 (%)</th>
<th>Registry N=40 (%)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with one procedure</td>
<td>37 (80.4)</td>
<td>32 (80.0)</td>
<td>0.084</td>
</tr>
<tr>
<td>Patients with two procedures</td>
<td>8 (17.4)</td>
<td>4 (10.0)</td>
<td></td>
</tr>
<tr>
<td>Patients with three procedures</td>
<td>0 (0)</td>
<td>4 (10.0)</td>
<td></td>
</tr>
<tr>
<td>Patients with four procedures</td>
<td>1 (2.2)</td>
<td>0 (0)</td>
<td></td>
</tr>
</tbody>
</table>

| Patients with PCI at baseline                     | 10 (21.7)      | 13 (32.5)        | 0.331   |
| Patients with PCI at baseline and follow-up       | 21 (45.7)      | 18 (45.0)        | 1.000   |

<table>
<thead>
<tr>
<th>Days from enrolment to patient’s first procedure</th>
<th>&lt;30 days</th>
<th>30–59 days</th>
<th>≥60 days</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>22.5 (6.5-64.75)</td>
<td>1.5 (0-7.25)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Procedures at baseline</th>
<th>BCIS Jeopardy Score (pre-PCI) at baseline*</th>
<th>BCIS Jeopardy Score (post-PCI) at baseline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trial n=31</td>
<td>4.3±3.7</td>
<td>2.4±2.5</td>
</tr>
<tr>
<td>Registry n=36</td>
<td>5.4±3.1</td>
<td>4.0±3.4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Procedures at baseline and follow-up</th>
<th>Urgent in-patient procedure</th>
<th>Outpatient procedure</th>
<th>Hospitalisation†</th>
<th>Complications related to angiogram‡</th>
<th>Culprit vessel uncertain</th>
<th>Culprit vessel identified</th>
<th>Graft only</th>
<th>Native artery only</th>
<th>Both graft and native artery</th>
<th>Multiple culprit lesions</th>
<th>PCI at baseline and follow-up</th>
<th>Thrombus aspiration</th>
<th>Rotational atherectomy</th>
<th>Intravascular ultrasound</th>
<th>Distal protection device</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trial n=57</td>
<td>27 (47.4)</td>
<td>30 (52.6)</td>
<td>28 (49.1)</td>
<td>1 (1.8)</td>
<td>27 (47.4)</td>
<td>30 (52.6)</td>
<td>17 (66.7)</td>
<td>12 (40.0)</td>
<td>1 (3.3)</td>
<td>3 (10.0)</td>
<td>24 (42.1)</td>
<td>1 (4.2)</td>
<td>4 (16.7)</td>
<td>2 (8.3)</td>
<td>3 (12.5)</td>
</tr>
<tr>
<td>Registry n=52</td>
<td>39 (75.0)</td>
<td>13 (25.0)</td>
<td>41 (78.8)</td>
<td>6 (11.5)</td>
<td>21 (40.4)</td>
<td>31 (59.6)</td>
<td>15 (48.4)</td>
<td>15 (48.4)</td>
<td>3 (3.2)</td>
<td>2 (6.5)</td>
<td>25 (48.1)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>3 (12.0)</td>
<td>2 (8.0)</td>
</tr>
</tbody>
</table>

Mean±SD and median (IQR) for non-normally distributed data.
*BCIS Jeopardy score not available in one registry patient because of poor-quality angiogram and limited data for right coronary artery (only still frame and not a run).
†Admission to hospital including at least one overnight stay.
‡Complications in trial (N=1) was worsening renal function after angiography; complications in registry (N=6) were side branch abrupt closure, main branch distal embolisation into filter, no reflow, dissection post-angioplasty (+haematoma > 5 cm in same patient), pulmonary oedema on angiography table, side branch new/worsened thrombus.
BCIS, British Cardiovascular Intervention Society; PCI, percutaneous coronary intervention.
Table 4: Primary and secondary outcomes over follow-up period (≥18 months; median 694 (IQR 558–841) days)

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Trial N=60</th>
<th>Registry N=73</th>
<th>HR (registry vs trial) (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary efficacy outcome</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Composite of all-cause mortality, rehospitalisation for refractory ischaemia/angina, MI and HF</td>
<td>26 (43%)</td>
<td>36 (49%)</td>
<td>1.14 (0.69 to 1.89)</td>
</tr>
<tr>
<td><strong>Primary safety outcome</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Composite of bleeding (BARC≥2), stroke, procedure-related MI and worsening renal function during the index hospitalisation</td>
<td>17 (28%)</td>
<td>16 (22%)</td>
<td>0.74 (0.37 to 1.46)</td>
</tr>
<tr>
<td>Experienced both primary efficacy and safety outcomes</td>
<td>10 (17%)</td>
<td>8 (11%)</td>
<td>0.64 (0.25 to 1.63)</td>
</tr>
<tr>
<td>Experienced either primary efficacy or safety outcomes</td>
<td>33 (55%)</td>
<td>44 (60%)</td>
<td>1.05 (0.67 to 1.65)</td>
</tr>
<tr>
<td><strong>Components of primary efficacy outcome</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All-cause mortality</td>
<td>8 (13%)</td>
<td>17 (23%)</td>
<td></td>
</tr>
<tr>
<td>Cardiovascular death</td>
<td>2 (3%)</td>
<td>10 (14%)</td>
<td></td>
</tr>
<tr>
<td>Non-cardiovascular death</td>
<td>4 (7%)</td>
<td>5 (7%)</td>
<td></td>
</tr>
<tr>
<td>Unknown cause of death</td>
<td>2 (3%)</td>
<td>2 (3%)</td>
<td></td>
</tr>
<tr>
<td>Rehospitalisation for refractory ischaemia/angina</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td></td>
</tr>
<tr>
<td>Non-fatal MI</td>
<td>22 (37%)</td>
<td>18 (25%)</td>
<td></td>
</tr>
<tr>
<td>HF</td>
<td>7 (12%)</td>
<td>11 (15%)</td>
<td></td>
</tr>
<tr>
<td><strong>Primary efficacy outcome at 12months</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Composite of all-cause mortality, rehospitalisation for refractory ischaemia/angina, MI and HF</td>
<td>20 (33%)</td>
<td>23 (32%)</td>
<td></td>
</tr>
<tr>
<td>All-cause mortality at 12 months</td>
<td>5 (8%)</td>
<td>9 (12%)</td>
<td></td>
</tr>
<tr>
<td><strong>Components of primary safety outcome</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bleeding (BARC 2–4)</td>
<td>11 (18%)</td>
<td>10 (14%)</td>
<td></td>
</tr>
<tr>
<td>Stroke</td>
<td>0 (0%)</td>
<td>2 (3%)</td>
<td></td>
</tr>
<tr>
<td>Procedure-related MI</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td></td>
</tr>
<tr>
<td>Worsening renal function during the index hospitalisation</td>
<td>8 (13%)</td>
<td>5 (7%)</td>
<td></td>
</tr>
<tr>
<td><strong>Primary safety outcome at 12months</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Composite of bleeding (BARC≥2), stroke, procedure-related MI and worsening renal function during the index hospitalisation</td>
<td>12 (20%)</td>
<td>14 (19%)</td>
<td></td>
</tr>
<tr>
<td><strong>Other secondary outcomes</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total number of SAE</td>
<td>170</td>
<td>117</td>
<td></td>
</tr>
<tr>
<td>Number of patients with a SAE</td>
<td>40 (67%)</td>
<td>49 (67%)</td>
<td></td>
</tr>
<tr>
<td>Number of SAEs per patient, median (IQR)</td>
<td>1(0, 2)</td>
<td>1(0, 2)</td>
<td></td>
</tr>
<tr>
<td><strong>Number of patients experiencing</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rehospitalisation</td>
<td>39 (65%)</td>
<td>47 (64%)</td>
<td></td>
</tr>
<tr>
<td>Invasive management (coronary angiography)</td>
<td>46 (77%)</td>
<td>40 (55%)</td>
<td></td>
</tr>
<tr>
<td>PCI</td>
<td>21 (35%)</td>
<td>18 (25%)</td>
<td></td>
</tr>
<tr>
<td>Redo CABG</td>
<td>0 (-)</td>
<td>1 (1%)</td>
<td></td>
</tr>
<tr>
<td>Coronary revascularisation (PCI or CABG)</td>
<td>21 (35%)</td>
<td>18 (25%)</td>
<td></td>
</tr>
<tr>
<td><strong>Quality of life and angina</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EQ-VAS health status, 6 months, median (IQR)</td>
<td>75 (60-80)</td>
<td>50 (40-75)</td>
<td></td>
</tr>
<tr>
<td>EQ-SD-5L score, 6 months, median (IQR)</td>
<td>0.82 (0.53-0.94)</td>
<td>0.61 (0.29-0.82)</td>
<td></td>
</tr>
<tr>
<td>CCS angina class, 6 months, median (IQR)</td>
<td>3.0 (1.0-3.0)</td>
<td>3.0 (2.0-4.0)</td>
<td></td>
</tr>
<tr>
<td>EQ-VAS health status, 12 months, median (IQR)</td>
<td>70 (50-80)</td>
<td>58 (40-75)</td>
<td></td>
</tr>
<tr>
<td>EQ-SD-5L score, 12 months, median (IQR)</td>
<td>0.82 (0.62-0.95)</td>
<td>0.78 (0.50-0.89)</td>
<td></td>
</tr>
<tr>
<td>CCS angina class, 12 months, median (IQR)</td>
<td>3.0 (3.0-4.0)</td>
<td>3.0 (2.0-4.0)</td>
<td></td>
</tr>
</tbody>
</table>

HRs and corresponding 95% CI from an unadjusted Cox model are given for the time from study entry to occurrence of primary outcomes only, comparing the registry to the trial group. Median (IQRs) are used for non-normally distributed data. Follow-up period was over median 694 (IQR 558–841) days.

BARC, Bleeding Academic Research Consortium; CABG, coronary artery bypass graft; CCS, Canadian Cardiovascular Society; EQ-SD-5L, EuroQol 5 Dimensions 5 Levels; EQ-VAS, EuroQol Visual Analogue Scale; HF, heart failure; MI, myocardial infarction; PCI, percutaneous coronary intervention; SAE, serious adverse event.
outcome. When considered together (efficacy or safety), the rates were very similar between the groups. There was a lower proportion in the registry group experiencing both outcomes, but these events were very small in number.

Kaplan-Meier survival curves (figure 2) reveal that health outcomes in the trial and registry groups were similar during follow-up. Compared with the trial group, all-cause mortality and cardiovascular death occurred more often in the registry group, but non-fatal MI and worsening renal function during the index hospitalisation occurred less often (table 4). Two-thirds of patients in both groups experienced a serious adverse event (table 4). Redo CABG occurred in only one registry patient and in none of the trial participants (table 4).

**Health status**

Compared to the trial group, the median EQ-VAS health status in the registry group was 25 points lower (worse) at 6 months, and 12 points lower at 12 months (table 4).

**Angina**

The CCS angina class was similar between the groups at 6 months (median (IQR) trial 3 (1-3) vs registry 3 (2-4)) and 12 months (median (IQR) trial 3 (3-4) vs registry 3 (2-4)) (table 4).

**DISCUSSION**

The main findings of our study are, compared with the trial group, in the registry group: (1) multimorbidity, functional limitation, frailty and impaired health status were more pronounced; (2) changes to medication were more often made because of recurrent angina but less often made for standard optimisation of secondary prevention; (3) in invasively managed patients, the extent of jeopardised myocardium was similarly high and the culprit lesion was identified in half, and revascularisation by PCI was performed on one third; (4) health-related quality of life was lower at baseline, 6 and 12 months and (5) there was a fourfold increased risk of cardiovascular death, although power was limited. Overall, our study provides novel, contemporary insights into an understudied subgroup of ACS patients with a substantial health burden.

Our registry-based trial provided a framework for information to be prospectively gathered on patients who may have been eligible for randomisation but were not, including the reasons for not being randomised. Registry participation reflected physician and/or patient preferences for one form of treatment over another. These beliefs substantially limited enrolment into the randomised trial. This finding has implications for the design and funding of future trials in this population. Moreover, the finding in the comparison of the
randomised trial groups that health outcomes were not different with invasive management versus conservative management supports the notion that enrolment rates could be increased by education of physicians and patients.21 Our trial results broadly reflect equipoise between the randomised strategies which should enhance confidence to support enrolment into a future randomised trial.

Compared with trial participation, registry participation was associated with a fourfold higher likelihood of cardiovascular death, with the caveat that event rates were very low for this outcome. This prognostic association may be partly explained by the greater burden of cardiovascular health problems at baseline, including HF and valve disease. Compared with trial patients, registry patients had more medication changes for recurrent angina—this may be partly explained by some registry patients having symptoms which were not stabilised and/or refractory ischaemia (both reasons for exclusion from the randomised trial) (figure 1). However, up-titration of medical therapy for secondary prevention occurred less often in the registry group, implying less intensive management, less scope for therapy improvements or both. The results highlight the substantial levels of morbidity, polypharmacy and adverse health outcomes in this group. The clinical course of two participants is illustrated (online supplemental figures 1 and 2).

Advances in interventional management
In our trial, invasive management was selected in 36 (49%) of registry participants at baseline, but PCI was performed in only 15 (36%) of these patients. The lower PCI rate in our population may be explained by the complex nature of native vessel and graft disease, lack of a clear culprit (in almost half), and, arguably, lack of definitive evidence in support of the benefits of PCI in this population.

PCI continues to evolve with technical advances potentially leading to improvements in safety and procedural success (online supplemental discussion).

Feasibility of a future substantive trial in patients with an NSTE-ACS and prior CABG
About one in 10–15 NSTE-ACS patients have a prior CABG (online supplemental table 1).6 This proportion is likely to remain stable in the coming years reflecting revascularisation practices in the past decade and increasing longevity. Many participants in this study were elderly, frail and multimorbid. Screening and obtaining informed consent were time-consuming for research staff. Medical decisions during urgent care may happen out-with office hours when research staff availability was limited. Medical information was commonly lacking at the time of hospitalisation, for example, graft history, limited recall by patients. These considerations present logistical barriers to enrolling patients into a randomised trial.

High event rates in patients with an NSTE-ACS and prior CABG
Almost half of the participants in both groups experienced a primary efficacy outcome event (table 4). In contemporary trials involving NSTE-ACS patients, the 12-month major adverse cardiac event (MACE) rate is usually 8%–10%, which is very much lower than observed in this study’s patients. The proportion of affected patients increased substantially during longer-term follow-up beyond 12 months. Again, this progressive accrual of adverse cardiac events over time contrasts with other trials in NSTE-ACS patients in which cardiac events may plateau over time. The older age and universal presence of multi-morbidity probably explain the differences in prognosis between NSTE-ACS patients with versus without prior CABG. Considering future trials in NSTE-ACS patients with prior CABG, there are considerable logistical challenges to enrolment but, however, the event rate implies that the sample size may be lower than for other populations in which primary outcome event rates are expectedly lower.

Limitations
Our pilot trial was not powered to assess for between-group differences in the rates of the serious adverse events contributing to the prespecified efficacy and safety outcomes. The sample size was small, with resultant wide confidence intervals. Both groups included patients that were managed differently (PCI vs medical therapy), thereby confounding between-group comparisons.

CONCLUSION AND POTENTIAL VALUE OF RESULTS
Since clinical trials usually excluded patients with prior CABG, practice guidelines are not evidence based with respect to this group. In real-world practice, clinicians lack relevant information to inform decision making. Our trial and registry may be helpful in the design of clinical trials in this patient group.

Author affiliations
1Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK
2West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital, Clydebank, UK
3Cardiology, Glasgow Royal Infirmary, Glasgow, UK
4Cardiology, Western Infirmary, Glasgow, UK
5Cardiology, Royal Alexandra Hospital, Paisley, UK
6Cardiology, Royal Blackburn Hospital, Blackburn, UK
7Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK
8Health Economics and Health Technology Assessment, University of Glasgow, Glasgow, UK
9Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK

Twitter Kenneth Mangion @kenneth_mangion and Colin Berry @ColinBerryMD

Contributors All authors meet all four ICMJE criteria for authorship. MMYL and AB coordinated study, enrolled patients, collected clinical data; MMYL also coordinated Clinical Event Committee. MCP, PR, JS and CEJ: clinical Event Committee. APR, CB, INFI and KPB: local principal investigators. MM, AS, SHMH, EEP, CLM, AJC and NBB: enrolled patients, collected clinical data. DSC and KM: collected clinical data. PC, NPS: angiographic analyses for BCIS-1 Jeopardy Score. OW: study design and health economics. IFo, AM and SJEB: biostatistics. CB: chief investigator.
Funding CB has received research support from the British Heart Foundation (PG/17/2532884, FS/17/26/32744, and RE/18/6134217) and the Medical Research Council (MR/S005714/1). KM and NS were supported by BHF Clinical Training Fellowships (FS/15/54/31639; FS/17/26/32744). This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests CB is employed by the University of Glasgow, which holds consultancy and/or research agreements with companies that have commercial interests in the diagnosis and treatment of ischaemic heart disease, including Abbott Vascular, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, HeartFlow, Menarini Farmaceutica, Opson, Philips and Siemens Healthcare. There are no other relevant personal disclosures.

Patient consent for publication Not required.

Ethics approval The study was reviewed and approved by the West of Scotland National Health Service Research Ethics Service (Reference 11-WS-0116).

Provenance and peer review Not commissioned; internally peer reviewed.

Data availability statement The data that support the findings of this study are available from the corresponding author on reasonable request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iDs
Matthew M Y Lee http://orcid.org/0000-0001-9213-2067
Mark C Petrie http://orcid.org/0000-0003-1350-1544
Paul Rocchiccioli http://orcid.org/0000-0003-1350-1544
Kenneth Mangion http://orcid.org/0000-0001-5047-0885
Ian Ford http://orcid.org/0000-0001-5927-1823
Olivia Wu http://orcid.org/0000-0002-0570-6016
Sarah J E Barry http://orcid.org/0000-0003-3039-8729
Colin Berry http://orcid.org/0000-0002-4547-8636

REFERENCES